Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy
Phase of Trial: Phase III
Latest Information Update: 27 May 2017
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 20 May 2017 Planned End Date changed from 31 Jul 2018 to 31 Jul 2025.
- 23 Nov 2014 Planned number of patients changed from 15 to 30 as reported by ClinicalTrials.gov.